JPRN-UMIN000018964已完成未知
Japanese research for patients with non-metastatic castration resistant prostate cancer - enzalutamide - JCASTRE-Zero
Kagawa University Faculty of Medicine0 个研究点目标入组 60 人开始时间: 2015年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) Patients with history of any chemotherapy (including estramustine phosphate sodium hydrate (JAN)), or treatment with enzalutamide or abiraterone acetate 2) Patients with history of steroid usage as treatment for prostate cancer 3) Patients with history of 5-alpha-reductase inhibitor, estrogen or steroidal antiandrogen within past 4 weeks prior to initial administration of enzalutamide 4) Patients with history of malignant tumor other than prostate cancer within past 3 years 5) Patients with history of seizure or predisposing disease of seizure 6) Patients with severe liver dysfunction 7) Patients with a previous history of hypersensitivity to any component of drugs which will be administered in this study 8) Patients who considered to be inappropriate for the study participation by the investigator.
研究者
相似试验
已完成
不适用
Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - EnzalutamideProstate CancerNCT02588001Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan60
已完成
2 期
Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.JPRN-jRCT2080223607ZENYAKU KOGYO CO., LTD.33
尚未招募
不适用
Multicenter registry study of Japanese patients with inflammatory bowel disease with COVID-19inflammatory bowel disease COVID-19JPRN-UMIN000040656Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine200
已完成
2 期
Japan multi-center study: Diagnostic and therapeutic ERC using a short double-balloon endoscope in patients with altered GI anatomybiliary diseaseJPRN-UMIN000010375Jichi Medical University240
进行中（未招募）
3 期
An extension study for seven patients in Japan with neuromyelitis optica spectrum disorder who completed the open-label period of study CD-IA-MEDI-551-1155 of InebilizumabJPRN-jRCT2051210017Sato Toshiyuki7